drugset / Trial / NCT04220944
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
Phase 1
Active not recruiting
45 enrolled
Shanghai Zhongshan Hospital
Innovent Biologics (Suzhou) Co. Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Efficacy and Safety of Locoregional treatments Combined With PD-1 Inhibitor in Patients With Unresectable Hepatocellular Carcinoma.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2024-10-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |